Trimeris Inc. (NASDAQ:TRMS) is feeling a little after-hour pressure. Roche and Trimeris today provided an update on their combined efforts to offer a needle-free device which has been investigated for use with FUZEON® (enfuvirtide).
Based on comprehensive assessment of the clinical program, as well a significant delay in achieving U.S. regulatory approval due to the time required to generate additional data, Roche and Trimeris are withdrawing a supplemental application for approval to market the Biojector® 2000 device.
This device is known as “B2000” and is manufactured by Bioject Medical Technologies, Inc. (NASDAQ:BJCT) for use with FUZEON. Importantly, Roche and Trimeris believe that patients who are currently administering FUZEON with the device through an existing program or clinical trial may continue to do so, provided that the precautions in the current FUZEON label regarding use with B2000 are followed. Roche and Trimeris noted that they recognize that B2000 is commercially available for general use.
There is no activity seen in BJCT shares. Trimeris (TRMS) originally saw a 10% drop in after-hours, but now shares are are down only about 4% at $7.82. Shares were up almost 4% in regualar trading to close at $8.21 today. Trimeris has a $182 million market cap and it is actually profitable. This may be a negative headline, but it has other oars in the water. Over the last year shares have traded as as low as $5.34 and as high as $13.85.
Jon C. Ogg
October 3, 2007
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
